SOCIOECONOMIC AND DEMOGRAPHIC FACTORS ASSOCIATED WITH FAILURE IN HELICOBACTER PYLORI ERADICATION USING THE STANDARD TRIPLE THERAPY. Data for improving the treatment choice and its performance.
Gastroenterology and Hepatology from Bed to Bench,
26 January 2021
Background: the efficacy of the standard triple therapy (STT) for H. pylori eradication has decreased with the rise of antibiotic resistance. Other factors could influence the eradication failure, although the available results are conflicting.
Aim: to evaluate the influence of socioeconomic and demographic factors on the eradication rate of H. pylori, using standard triple therapy.
Methods: retrospective study, including adults with H. pylori infection treated de novo with STT (proton pump inhibitor, amoxicillin and clarithromycin). Eradication success was checked by 13C-urea breath test. Demographic and socioeconomics variables were evaluated and correlated with eradication treatment outcome. The confounder variables were controlled by logistic regression analysis.
Results: Out of 902 patients with H. pylori diagnosis 693 achieve inclusion criteria (average age 53 years; females 55.2%). Non-significant differences were observed in relation to economics income between rural and urban areas (p=0.316). The eradication rate of H. pylori was 71.1%; male 78.9% vs female 65.9%; urban area 73.4% vs rural area 64.1%. In reference to age, income and nationality the eradication rates were similar in all groups. According to logistic regression analysis, females had almost twice more likelihood of eradication failure in relation to males (OR 1.92; 95%CI: 1.38–2.72); and rural residents had OR 1.55 (95%CI: 1.03–2.33) for having eradication failure in contrast with urban population.
Conclusions: Female sex and rural residence are factors associated to H. Pylori eradication failure with standard triple therapy.
- Helicobacter pylori. Demographic factors. Socioeconomic factors. Eradication failure. Standard triple therapy.
Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196-202.
Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-76.
Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:773–9.
Mentis A, Lehours P, Mégraud F. Epidemiology and Diagnosis of Helicobacter pylori infection. Helicobacter 2018; 20 (Suppl. 1):1–7.
den Hollander WJ, Holster IL, den Hoed CM, van Deurzen F, van Vuuren AJ, Jaddoe VW et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. J Gastroenterol Hepatol. 2013;28(11): doi:10.1111/jgh.12315.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016; 43: 514–33.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42.
Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol. 2013;36(6):375-81.
Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018;12(8):819–27.
Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol. 2016;39(10):697-721.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
Chey WD, Leontiadis GI , Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212–38.
Cai W, Zhou L, Ren W, Deng L, Yu M. Variables influencing outcome of Helicobacter pylori eradication therapy in South China. Helicobacter. 2009;14(5):91-6.
Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801-7.
Navarro-Jarabo JM, Fernandez-Sanchez F, Fernandez-Moreno N, Hervas-Molina AJ, Casado-Caballero F, Puente-Gutierrez JJ, et al. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. Digestion. 2015;92(2):78-82.
Itskoviz D, Boltin D, Leibovitzh H, Tsadok Perets T, Comaneshter D, Cohen A et al. Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig Liver Dis. 2017;49(7):764-8.
Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59(6):1235-43.
Lim SG, ParK RW, Shin SJ, Yoon D, Kang JK, Hwang JC et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Digestive and Liver Disease. 2016;48:385–90.
Chang YW, Ko WJ, Oh CH, Park YM, Oh SJ, Moon JR et al. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med. 2018 Jun 14. doi: 10.3904/kjim.2018.054.
Kim BJ, Kim HS, Song HJ, Chung IK, Kim GH, Kim BW et al. Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis. J Korean Med Sci. 2016;31(8):1246-53.
Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65(1):9-18.
Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist. 2018;11:205-11.
De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19(4):409-14.
Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010;44(8):536-43.
Lefebvre M, Chang HJ, Morse A, van Zanten MV, Goodman KJ and CANHelp Working Group. Adherence and barriers to H. pylori treatment in Arctic Canada. Int J Circumpolar Health 2013;72: 22791 - http://dx.doi.org/10.3402/ijch.v72i0.22791.
Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S et al. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22(4). doi: 10.1111/hel.12383.
Vale FF1, Vítor JM. Transmission pathway of Helicobacter pylori: does food play a role in rural and urban areas? Int J Food Microbiol. 2010;138(1-2):1-12.
Cheng H, Hu F, Zhang L, Yang G, Ma J, Hu J et al. Prevalence of Helicobacter pylori infection and identification of risk factors in rural and urban Beijing, China. Helicobacter. 2009;14(2):128-33.
Miernyk KM, Bulkow LR, Gold BD, Bruce MG, Hurlburt DH, Griffin PM et al. Prevalence of Helicobacter pylori among Alaskans: Factors associated with infection and comparison of urea breath test and anti-Helicobacter pylori IgG antibodies. Helicobacter. 2018;23(3):e12482.
- Abstract Viewed: 0 times